Acceptability of HPTN 077. The George Washington University HPTN Clinical Research Site 16 June 2016

Similar documents
Engaging and Recruiting Black MSM (BMSM) in the US

December 14, Letter of Amendment 1 Version 2.0 HVTN 704/HPTN 085

The role of Integrase Inhibitors during HIV prevention

HPTN 061: The Brothers Study

The Feasibility of HIV Prevention Cohort Studies among Men who have Sex with Men (MSM) in sub-saharan Africa

On the Horizon for Consideration: Biomedical Advances in HIV Prevention

Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D.

Novel HIV Prevention Methods for Women

The Open Label Trial Past and Present

The Open Label Trial Past and Present

IAPAC Summit Daily And Intermittent PrEP

Biomedical HIV Prevention & PrEP Pre exposure Prophylaxis 2013

Multiple choice questions: ANSWERS

Uptake and Utilization of PrEP Among Black MSM: Why Race Matters (HPTN 073)

PrEP: Pre Exposure Prophylaxis

PrEPX frequently asked questions version 1

PrEP and Black MSM ANTIRETROVIRALS AND HIV PREVENTION: A CONVERSATION WITH KEY OPINION LEADERS ABOUT A NEW PARADIGM FENWAY HEALTH, 10/29/13

Understanding the Results of VOICE

Using anti-hiv drugs for prevention

QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE

PrEP Home Checklist v1.0

In collaboration with GLOBAL HEALTH SCIENCES, UNIVERSITY OF CALIFORNIA, SAN FRANCISCO. Training workshop

Shebeen Attendees Perceptions of HIV Pre-Exposure Prophylaxis (PrEP) in KwaZulu-Natal Province, South Africa

PrEP adherence in Black MSM in HPTN 073 and Beyond

Impact of the Proposed Cuts to HIV/AIDS Research. Kevin Fisher AVAC September 7, 2017

NYS PrEP Programming. Lyn Stevens, NP, MS, ACRN Office of the Medical Director, AIDS Institute PrEP Monitoring in NYC and NYS February 19, 2016

HVTN 505 Study HIV Vaccine Candidate Not Effective

PREP CASE MANAGEMENT: PURPOSE, PROCESS, AND OUTCOMES FOR HIV VULNERABLE PREP INITIATES PRESENTED BY MATT LOWTHER

Update on Biomedical Prevention. Thomas C. Quinn, MD, MSc

Pre-Exposure Topical Microbicides and Oral Prophylaxis Trials:

Potential Impact on HIV Incidence of Increasing Viral Suppression among HIV-positive MSM in Baltimore: Mathematical Modelling for HPTN 078

Inspiring HIV Prevention Innovations for Women. IPM Satellite Event Durban, 13 th June 2017 Annalene Nel

Letter of Amendment # 3 to:

ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF

Financial Incentives, Linkage to Care and Viral Suppression HPTN 065 (TLC-Plus) Study. Wafaa El-Sadr ICAP at Columbia University New York, NY

PrEP for Women. Together, we can change the course of the HIV epidemic one woman at a time.

Hormonal contraception and HIV risk

Available In person Courses

Data to Care: Improving Health Across the HIV Care Continuum in Colorado

Clinical Trials Network

PrEP May Cause a Revolution in HIV Prevention: Time to Get Ready

Clinical Education Initiative PRE-EXPOSURE PROPHYLAXIS. Speaker: Antonia Urbina, MD

Supplementary Material Table 5. Ongoing PrEP studies among young key population, young people, and key populations. Age range. Study name and location

Zero HIV infections Zero HIV deaths Zero HIV stigma. Stephanie Cohen, MD, MPH on behalf of the Getting to Zero Consortium

PrEP in young African women: Rationale & lessons from HPTN 082

Fulton County Board of Health Strategy to End the HIV Epidemic in Fulton County

Guidelines for Implementing Pre-Exposure Prophylaxis For The Prevention of HIV in Youth Peter Havens, MD MS Draft:

Overcoming Structural Barriers to HIV Prevention

November 9, Clarification Memo 1 Version 3.0 HVTN 704/HPTN 085

Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City

Strategic use of antiretroviral drugs to prevent HIV transmission

Informed Consent Flipchart. Version 1.0, 30 Jan 2018

2016 NYS HIV Quality of Care Review

HPTN 071 (PopART) Population Effects of Antiretroviral Therapy to Reduce HIV Transmission

Moving PrEP Forward. Where We Are & Where We Need to Go. Christopher Hurt, MD Assistant Professor of Medicine Division of Infectious Diseases

ART and Prevention: What do we know?

Long Acting HIV Drugs for Prevention: what are the data? Pep Coll AIDS Research Institute-IrsiCaixa Fight AIDS Foundation BCN Checkpoint

A Sub-Study Comparing Acceptability and Adherence of Daily or Non-Daily Pre-Exposure Regimens Between Young and Older South African Women

Pre-Exposure Prophylaxis Perspectives from the Southeast. Christopher Hurt, MD Assistant Professor of Medicine Division of Infectious Diseases

CHARISMA s Impact on HOPE participants at Wits RHI

Pre-exposure Prophylaxis. Robert M Grant October 2014

Evolving HIV Treatment Paradigms What we need to know

Counselling Should: Recognize that behaviour change is difficult and human beings are not perfect

Engaging a Hidden Population to Stop HIV

Increasing PrEP Awareness and Supporting PrEP within Your Jurisdiction

American Men s Internet Survey (AMIS)

What do we know about HIV trial design for adolescents?

Letter of Amendment # 3 to:

HIV Navigation Services (HNS)

HPTN Community Working Group 2017 IAS Debrief

PERFORMANCE INDICATOR REFERENCE SHEETS FOR KEY POPULATIONS

On-going Integrated Strategy Interventions to Maximize ART and PrEP Effectiveness in Peru

Ending The HIV/AIDS Epidemic in America

PATH FOR TRIPLES BUSHAUNA FREEMAN MICHAEL BLANK, P.I. SUMR PROGRAM 2016 PHILADELPHIA, PA AUGUST 18, 2016

Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world?

Recruiting MSM, Transgender & minority populations for HIV research

PrEP in young African women: Rationale & lessons from HPTN 082 (and other studiesp

Pre-Exposure Prophylaxis (PrEP) for HIV Infection

PrEP Implementation in San Francisco. Michael Barajas- Citywide PrEP Navigator San Francisco City Clinic San Francisco Department of Public Health

11/8/2016. The Challenge of HIV Treatment

Cabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team. 17 th HIV-HEPPK June 2016

Chart Pack National Survey of Young Adults on HIV/AIDS

Community engagement in HPTN 071 (PopART) trial: lessons learnt from implementing a novel data collection Technique photo-journal

South African Guidelines for the Safe Use of. Dr. Oscar Radebe

Where We Have Been and Where We are Going. Ian McGowan MD PhD FRCP

PrEP: Getting to the Tipping Point

Community-Based TasP Trials: Updates and Projected Contributions. Reaching the target: Lessons from HPTN 071 (PopART) Sarah Fidler

Best Practices for maintaining relationships with CBOs & stakeholders providing services to MSM and/or transgender people

Prevenção do HIV e o papel dos inibidores da integrasse

California Department of Public Health (CDPH), Office of AIDS (OA) Monthly Report April 2018

What We Will Learn From the REACH Study

Stigma and HIV. Maria E. Alvarez, MPA. LEAD PUBLIC HEALTH ADVISOR Team Lead, Capacity Building Branch Partnerships Team

PrEP for HIV Prevention. Adult Clinical Guideline from the New York State Department of Health AIDS Institute

Successful results of clinical trials

What do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women

OR: Steps you can take in the clinic to prevent HIV infections

Modelling HIV Transmission and Treatment for US MSM to Estimate the Impact of HPTN 078 on HIV Incidence

California HIV/AIDS Research Program

HIV PREP THE NEWEST TOOL IN THE BOX

Treatment as Prevention in India: What will it take?

Transcription:

Acceptability of HPTN 077 The George Washington University HPTN Clinical Research Site 16 June 2016

Outline The epidemic in DC Prior HPTN studies, the context for injections Our experience with HPTN 077 Discussion

The HIV Epidemic in DC Annual Epidemiology & Surveillance Report, 2013 (final) www.doh.dc.gov

The HIV Epidemic in DC Annual Epidemiology & Surveillance Report, 2013 (final) www.doh.dc.gov

The HIV Epidemic in DC Annual Epidemiology & Surveillance Report, 2013 (final) www.doh.dc.gov

Completed HPTN Studies at GW HPTN 061 To determine the feasibility and acceptability of a multicomponent intervention for Black MSM, including peer health system navigation (N=227 in DC) HPTN 064 To determine the feasibility of estimating HIV incidence in women at risk for HIV and evaluate feasibility of enrolling/following cohort of women (N=210 in DC) HPTN 069 Phase II study of safety and tolerability of maraviroc as PrEP (N=70 in DC) HPTN 073 Truvada as PrEP + C4 counseling among black MSM (N=75 in DC)

Ongoing and new HPTN Studies at GW HPTN 077 Early Phase II study of safety and tolerability of long acting injectable PrEP using GSK744LA (N=23 in DC, follow up ongoing) HPTN 085 A phase 2b study of VRC01 in reducing acquisition of HIV-1 infection among men and transgender persons who have sex with men (just opened!) HPTN 083 Phase study of injectable cabotegravir in reducing acquisition of HIV-1 infection among men and transgender persons who have sex with men (coming soon!)

Other studies being conducted in our public health research clinic Telemedicine for transgender women of color Overcoming structural barriers to HIV prevention utilization by Black MSM Sexual violence / biomarkers in pre- and post menopausal women Molecular epidemiology Survey research Culturally-tailored PrEP resource center for young Black MSM

We are having a great experience with HPTN 077 Retention currently 100%! Enrolled 23 out of target 22! A lot of it was new since low risk, healthy people

Notes about recruitment and engagement CAB meetings, CAB mailing list Fliers at campuses Word of mouth Social media Craigslist Did not use our typical venue based approaches since for low risk people Differentiation between injectable vaccine vs. long acting ARV injectable

Short social media (e.g., facebook, twitter,, craigslist, grinder, etc.) script and print media with low risk specified Are you interested in helping to end the HIV epidemic? We are conducting a new NIH funded study of injectable medications that may one day help stop the spread of HIV and we are looking for a few HIV-negative, low risk, and healthy individuals. Eligible participants may be able to receive up to $1,175 over 2 years. If you or anyone you know might be interested in participating, please call 202 652 4709 or email gwuphc@gwu.edu Shorter social media (e.g., facebook, twitter, craigslist, grinder, etc.) script and print media Help prevent HIV! Join HPTN 077. Eligible participants may receive up to $1,175 over 2 years. Interested in participating? gwuphc@gwu.edu Shorter social media (e.g., facebook, twitter, craigslist, grinder, etc.) script and print media Are you at low risk for HIV? Join HPTN 077. Participants may receive up to $1,175 over 2 years. Interested in participating? gwuphc@gwu.edu HPTN 077 to help stop HIV. Participants may receive up to $1,175 over 2 years. Interested? gwuphc@gwu.edu Are you at low risk for HIV? Join HPTN 077 & test an injectable medication to prevent HIV. Interested in participating? gwuphc@gwu.edu Join HPTN 077 & test a non-vaccine injectable medication to prevent HIV. Interested in participating? gwuphc@gwu.edu

Issues about implementation Once understood not a vaccine, more acceptable Preferred more injections x 1 to fewer injections x 2 No one discontinued due to negative injection perception Easy to manage in pharmacy, clinic, data Very few AEs Clear protocol Excellent support of CMC and protocol team

Discussion and Q&A

ACKNOWLEDGEMENTS The HIV Prevention Trials Network is sponsored by the National Institute of Allergy and Infectious Diseases, the National Institute of Mental Health, and the National Institute on Drug Abuse, all components of the U.S. National Institutes of Health. Thank you We are looking forward to working together on HPTN 083! Questions?